Evaluation of the Frequency of Side Effects of Drugs Used in the Treatment of COVID-19: A Retrospective Study COVID-19 Tedavisinde Kullanılan İlaçların Yan Etki Sıklığının Değerlendirilmesi: Bir Retrospektif Araştırma


ERYILMAZ EREN E., Çelik İ., Eren D., Arman Firat E., Topaloğlu U. S., Kara M., ...Daha Fazla

Turkiye Klinikleri Journal of Medical Sciences, cilt.41, sa.4, ss.410-415, 2021 (Scopus, TRDizin)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 41 Sayı: 4
  • Basım Tarihi: 2021
  • Doi Numarası: 10.5336/medsci.2020-78763
  • Dergi Adı: Turkiye Klinikleri Journal of Medical Sciences
  • Derginin Tarandığı İndeksler: Scopus, CAB Abstracts, CINAHL, EMBASE, Veterinary Science Database, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.410-415
  • Anahtar Kelimeler: Adverse effect, COVID-19, Favipiravir, Hydroxychloroquine, Macrolides
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Objective: It is aimed to determine the frequency of side effects seen in the use of antiviral, antibacterial and immunomodulatory drugs used in the treatment of coronavirus disease-2019 (COVID-19) in combination or monotherapy. Material and Methods: In this retrospective study, patients with a diagnosis of COVID-19 who received hydroxychloroquine, macrolide, and favipiravir treatments in combination or monotherapy were evaluated in terms of the development of side effects. Demographic and clinical data of the patients, other treatments they received and the side effects that occurred were recorded. Results: During the study period, data from 337 patients were ana-lyzed. The median age of the patients was 56 (19-94), and 184 (54.6%) were male. Hypertension was the most common comorbidity (29.9%). Diffuse infiltration was detected in 210 (62.3%) of 272 (80.7%) patients with pneumonia. Eighteen (5.3%) patients received only hydroxychloroquine, 86 (25.5%) had only macrolide, 193 (57.3%) had hydroxychloroquine and macrolide, and 40 (11.9%) had hydroxy-chloroquine, macrolide and favipiravir triple combination. Side effects were observed in 2 (11.1%) patients receiving hydroxychloroquine monotherapy, 4 (4.7%) patients receiving macrolide monotherapy, 55 (28.5%) patients receiving hydroxychloroquine-macrolide combina-tion, and 4 (10.0%) patients receiving hydroxychloroquine-macrolide-favipiravir combination. It was observed that the most common (12.9%) side effect in the group receiving the combination of hydroxychloroquine and macrolide was QT prolongation. The most common (7.3%) side effect of the gastrointestinal system was found to be nausea. Con-clusion: The frequency of side effects increases when antiviral, antibacterial and immunomodulatory drugs used for the treatment of COVID-19 are used in combination.